Increased frequency of TIGIT⁺CD73-CD8⁺ T cells with a TOX⁺ TCF-1low profile in patients with newly diagnosed and relapsed AML

References

• Lamble AJ, Lind EF. Targeting the immune microenvironment in acute myeloid leukemia: a focus on T cell immunity. Front Oncol. 2018;8:213. doi:10.3389/fonc.2018.00213.
   PubMed Web of Science ®Google Scholar
• Lichtenegger FS, Krupka C, Haubner S, Köhnke T, Subklewe M. Recent developments in immunotherapy of acute myeloid leukemia. J Hematol Oncol. 2017;10(1):142. doi:10.1186/s13045-017-0505-0.
   PubMed Web of Science ®Google Scholar
• Williams BA, Law A, Hunyadkurti J, Desilets S, Leyton JV, Keating A. Antibody therapies for acute myeloid leukemia: unconjugated, toxin-conjugated, radio-conjugated and multivalent formats. J Clin Med. 2019;8(8):8. doi:10.3390/jcm8081261.
   Web of Science ®Google Scholar
• Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670–13. doi:10.1016/j.immuni.2007.09.006.
   PubMed Web of Science ®Google Scholar
• Stamm H, Klingler F, Grossjohann EM, Muschhammer J, Vettorazzi E, Heuser M, Mock U, Thol F, Vohwinkel G, Latuske E, et al. Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene. 2018;37(39):5269–5280. doi:10.1038/s41388-018-0288-y.
   PubMed Web of Science ®Google Scholar
• Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC, Rybka WB, George MR, Zeng H, Zheng H, et al. T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8(+) T-cell exhaustion and poor clinical outcome in AML patients. Clin Cancer Res. 2016;22(12):3057–3066. doi:10.1158/1078-0432.CCR-15-2626.
   PubMed Web of Science ®Google Scholar
• Ackermann C, Smits M, Woost R, Eberhard JM, Peine S, Kummer S, Marget M, Kuntzen T, Kwok WW, Lohse AW, et al. HCV-specific CD4+ T cells of patients with acute and chronic HCV infection display high expression of TIGIT and other co-inhibitory molecules. Sci Rep. 2019;9(1):10624. doi:10.1038/s41598-019-47024-8.
   PubMed Web of Science ®Google Scholar
• Allard D, Allard B, Gaudreau PO, Chrobak P, Stagg J. CD73-adenosine: a next-generation target in immuno-oncology. Immunotherapy-Uk. 2016;8(2):145–163. doi:10.2217/imt.15.106.
   PubMed Web of Science ®Google Scholar
• Jiang T, Xu XF, Qiao M, Li X, Zhao C, Zhou F, Gao G, Wu F, Chen X, Su C, et al. Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers. BMC Cancer. 2018;18(1). ARTN 267. doi:10.1186/s12885-018-4073-7.
   Google Scholar
• Bastid J, Regairaz A, Bonnefoy N, Déjou C, Giustiniani J, Laheurte C, Cochaud S, Laprevotte E, Funck-Brentano E, Hemon P, et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res. 2015;3(3):254–265. doi:10.1158/2326-6066.Cir-14-0018.
   PubMed Web of Science ®Google Scholar
• Toth I, Le AQ, Hartjen P, Thomssen A, Matzat V, Lehmann C, Scheurich C, Beisel C, Busch P, Degen O, et al. Decreased frequency of CD73(+) CD8(+) T cells of HIV-infected patients correlates with immune activation and T cell exhaustion. J Leukocyte Biol. 2013;94(4):551–561. doi:10.1189/jlb.0113018.
   PubMed Web of Science ®Google Scholar
• Duhen T, Duhen R, Montler R, Moses J, Moudgil T, De Miranda NF, Goodall CP, Blair TC, Fox BA, McDermott JE, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018;9(1). ARTN 2724. doi:10.1038/s41467-018-05072-0.
   PubMedGoogle Scholar
• Mohme M, Schliffke S, Maire CL, Rünger A, Glau L, Mende KC, Matschke J, Gehbauer C, Akyüz N, Zapf S, et al. Immunophenotyping of newly diagnosed and recurrent glioblastoma defines distinct immune exhaustion profiles in peripheral and tumor-infiltrating lymphocytes. Clinical Cancer Research. 2018;24(17):4187–4200. doi:10.1158/1078-0432.Ccr-17-2617.
   PubMed Web of Science ®Google Scholar
• Zhang HY, Vijayan D, Li XY, Robson SC, Geetha N, Teng MWL, Smyth MJ. The role of NK cells and CD39 in the immunological control of tumor metastases. Oncoimmunology ARTN e1593809. 2019;8(6):e1593809. doi:10.1080/2162402X.2019.1593809.
   PubMed Web of Science ®Google Scholar
• Wieland D, Kemming J, Schuch A, Emmerich F, Knolle P, Neumann-Haefelin C, Held W, Zehn D, Hofmann M, Thimme R, et al. TCF1(+) hepatitis C virus-specific CD8(+) T cells are maintained after cessation of chronic antigen stimulation. Nat Commun. 2017;8(1):15050. doi:10.1038/ncomms15050.
   PubMed Web of Science ®Google Scholar
• Renkema KR, Huggins MA, Da Silva HB, Knutson TP, Henzler CM, Hamilton SE. KLRG1(+) memory CD8 T cells combine properties of short-lived effectors and long-lived memory. Journal of Immunology. 2020;205(4):1059–1069. doi:10.4049/jimmunol.1901512.
   PubMed Web of Science ®Google Scholar
• Kratchmarov R, Magun AM, Reiner SL. TCF1 expression marks self-renewing human CD8(+) T cells. Blood Adv. 2018;2(14):1685–1690. doi:10.1182/bloodadvances.2018016279.
   PubMed Web of Science ®Google Scholar
• Scott AC, Dundar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, Trivedi P, Menocal L, Appleby H, Camara S, et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019;571(7764):270-+. doi:10.1038/s41586-019-1324-y.
   PubMed Web of Science ®Google Scholar
• Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, Werner MT, Huang AC, Alexander KA, Wu JE, et al. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature. 2019;571(7764):211-+. doi:10.1038/s41586-019-1325-x.
   Web of Science ®Google Scholar
• Bono MR, Fernandez D, Flores-Santibanez F, Rosemblatt M, Sauma D. CD73 and CD39 ectonucleotidases in T cell differentiation: beyond immunosuppression. FEBS Lett. 2015;589(22):3454–3460. doi:10.1016/j.febslet.2015.07.027.
   PubMed Web of Science ®Google Scholar
• Huster KM, Busch V, Schiemann M, Linkemann K, Kerksiek KM, Wagner H, Busch DH. Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8(+) memory T cell subsets. P Natl Acad Sci USA. 2004;101(15):5610–5615. doi:10.1073/pnas.0308054101.
   PubMed Web of Science ®Google Scholar
• Kim K, Park S, Park SY, Kim G, Park SM, Cho J-W, Kim DH, Park YM, Koh YW, Kim HR, et al. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer. Genome Med. 2020;12(1). ARTN 22. doi:10.1186/s13073-020-00722-9.
   Web of Science ®Google Scholar
• Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz JS, Draenert R, Hiddemann W, Subklewe M. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol. 2015;8(1). ARTN 93. doi:10.1186/s13045-015-0189-2.
   PubMedGoogle Scholar
• Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al‐Hamal Z, Konopleva M, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125(9):1470–1481. doi:10.1002/cncr.31896.
   PubMed Web of Science ®Google Scholar
• Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, Kirkwood JM, Chen THT, Maurer M, Korman AJ, et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest. 2015;125(5):2046–2058. doi:10.1172/Jci80445.
   PubMed Web of Science ®Google Scholar
• Kong YX, Jia B, Zhao CC, Claxton DF, Sharma A, Annageldiyev C, Fotos JS, Zeng H, Paulson RF, Prabhu KS, et al. Downregulation of CD73 associates with T cell exhaustion in AML patients. J Hematol Oncol. 2019;12(1). ARTN 40. doi:10.1186/s13045-019-0728-3.
   Google Scholar
• Soleimani A, Farshchi HK, Mirzavi F, Zamani P, Ghaderi A, Amini Y, Khorrami S, Mashayekhi K, Jaafari MR. The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma. Biochimie. 2020;176:21–30. doi:10.1016/j.biochi.2020.06.001.
   PubMed Web of Science ®Google Scholar
• Ren ZH, Lin CZ, Cao W, Yang R, Lu W, Liu Z-Q, Chen Y-M, Yang X, Tian Z, Wang L-Z, et al. CD73 is associated with poor prognosis in HNSCC. Oncotarget. 2016;7(38):61690–61702. doi:10.18632/oncotarget.11435.
   PubMedGoogle Scholar
• Leclerc BG, Charlebois R, Chouinard G, Allard B, Pommey S, Saad F, Stagg J. CD73 expression is an independent prognostic factor in prostate cancer. Clinical Cancer Research. 2016;22(1):158–166. doi:10.1158/1078-0432.Ccr-15-1181.
   PubMed Web of Science ®Google Scholar
• Gaudreau PO, Allard B, Turcotte M, Stagg J. CD73-adenosine reduces immune responses and survival in ovarian cancer patients. Oncoimmunology. 2016;5(5):e1127496. doi:10.1080/2162402X.2015.1127496.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Yoshimura K, Kurabe N, Kahyo T, Kawase A, Tanahashi M, Ogawa H, Inui N, Funai K, Shinmura K, et al. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. Oncotarget. 2017;8(5):8738–8751. doi:10.18632/oncotarget.14434.
   PubMedGoogle Scholar
• Oh HK, Sin JI, Choi J, Park SH, Lee TS, Choi YS. Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration. J Gynecol Oncol. 2012;23(4):274–281. doi:10.3802/jgo.2012.23.4.274.
   PubMed Web of Science ®Google Scholar
• Cai XY, Wang XF, Li J, Dong J-N, Liu J-Q, Li N-P, Yun B, Xia R-L, Qin J, Sun Y-H, et al. High expression of CD39 in gastric cancer reduces patient outcome following radical resection. Oncol Lett. 2016;12(5):4080–4086. doi:10.3892/ol.2016.5189.
   PubMed Web of Science ®Google Scholar
• Kunzli BM, Bernlochner MI, Rath S, Käser S, Csizmadia E, Enjyoji K, Cowan P, d’Apice A, Dwyer K, Rosenberg R, et al. Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer. Purinergic Signal. 2011;7(2):231–241. doi:10.1007/s11302-011-9228-9.
   PubMed Web of Science ®Google Scholar
• Vaisitti T, Arruga F, Guerra G, Deaglio S. Ectonucleotidases in blood malignancies: a tale of surface markers and therapeutic targets. Front Immunol. 2019;10. ARTN 2301. doi:10.3389/fimmu.2019.02301.
   PubMed Web of Science ®Google Scholar
• Canale FP, Ramello MC, Nunez N, Furlan CLA, Bossio SN, Serrán MG, Boari JT, Del Castillo A, Ledesma M, Sedlik C, et al. CD39 expression defines cell exhaustion in tumor-infiltrating CD8(+) T cells. Cancer Res. 2018;78(1):115–128. doi:10.1158/0008-5472.Can-16-2684.
   PubMed Web of Science ®Google Scholar
• Thelen M, Lechner A, Wennhold K, Von Bergwelt-baildon M, Schlößer HA. CD39 expression defines cell exhaustion in tumor-infiltrating CD8(+) T cells—letter. Cancer Res. 2018;78(17):5173–5174. doi:10.1158/0008-5472.Can-18-0873.
   PubMed Web of Science ®Google Scholar
• Moesta AK, Li XY, Smyth MJ. Targeting CD39 in cancer. Nat Rev Immunol. 2020;20(12):739–755. doi:10.1038/s41577-020-0376-4.
   PubMed Web of Science ®Google Scholar
• Allard D, Allard B, Stagg J. On the mechanism of anti-CD39 immune checkpoint therapy. J Immunother Cancer ARTN e000186. 2020;8(1):e000186. doi:10.1136/jitc-2019-000186.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu S, Zhang B, Qiao L, Zhang Y, Zhang Y. T cell dysfunction and exhaustion in cancer. Front Cell Dev Biol. 2020;8:17. doi:10.3389/fcell.2020.00017.
   PubMed Web of Science ®Google Scholar
• Xin YJ, Hodge JP, Oliva C, Neftelinov ST, Hubbard-Lucey VM, Tang J. Trends in clinical development for PD-1/PD-L1 inhibitors. Nat Rev Drug Discov [published Online First: 2020/03/05]. 2020;19(3):163–164. doi:10.1038/d41573-019-00182-w.
   PubMed Web of Science ®Google Scholar
• Qin S, Xu LP, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1). doi:10.1186/s12943-019-1091-2. ARTN 155.
   Web of Science ®Google Scholar
• Wang YF, Hu JJ, Li YD, Xiao M, Wang H, Tian Q, Li Z, Tang J, Hu L, Tan Y, et al. The transcription factor TCF1 preserves the effector function of exhausted CD8 T cells during chronic viral infection. Front Immunol. 2019;10. ARTN 169. doi:10.3389/fimmu.2019.00169.
   Web of Science ®Google Scholar
• Utzschneider DT, Charmoy M, Chennupati V, Pousse L, Ferreira DP, Calderon-Copete S, Danilo M, Alfei F, Hofmann M, Wieland D, et al. T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity. 2016;45(2):415–427. doi:10.1016/j.immuni.2016.07.021.
   PubMed Web of Science ®Google Scholar
• Shan Q, Hu SE, Chen X, Danahy DB, Badovinac VP, Zang C, Xue HH. Ectopic Tcf1 expression instills a stem-like program in exhausted CD8(+) T cells to enhance viral and tumor immunity. Cell Mol Immunol. 2020. doi:10.1038/s41423-020-0436-5.
   PubMed Web of Science ®Google Scholar
• Mann TH, Kaech SM. CD8(+) T CELLS Tick-TOX, it’s time for T cell exhaustion. Nat Immunol. 2019;20(9):1092–1094. doi:10.1038/s41590-019-0478-y.
   PubMed Web of Science ®Google Scholar
• Seo H, Chen J, Gonzalez-Avalos E, Samaniego-Castruita D, Das A, Wang YH, López-Moyado IF, Georges RO, Zhang W, Onodera A, et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. P Natl Acad Sci USA. 2019;116(39):19761. doi:10.1073/pnas.1914896116.
   PubMed Web of Science ®Google Scholar